Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 17/20 | 0.56 |
| ▸ | PPARD | Q03181 | 12/20 | 0.56 |
| ▸ | PPARG | P37231 | 8/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13905169 | 0.90 | PPARA (0.46) | PPARAPPARDPPARG | |
| SCHEMBL3945538 | 0.90 | PPARA (0.45) | PPARAPPARDPPARG | |
| SCHEMBL13904975 | 0.87 | DDX3X (0.43) | PPARAPPARDPPARG | |
| SCHEMBL13899334 | 0.86 | PPARA (0.53) | PPARAPPARDPPARG | |
| SCHEMBL13899063 | 0.85 | PPARD (0.61) | PPARAPPARDPPARG | |
| SCHEMBL14505660 | 0.85 | PPARA (0.50) | PPARAPPARDPPARG | |
| SCHEMBL13899317 | 0.80 | PPARA (0.55) | PPARAPPARDPPARG | |
| SCHEMBL13899054 | 0.78 | PPARA (0.54) | PPARAPPARDPPARG | |
| SCHEMBL13899314 | 0.77 | PPARA (0.53) | PPARAPPARDPPARG | |
| SCHEMBL13899326 | 0.77 | PPARA (0.52) | PPARAPPARDPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507832-B2 | Triazole PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507832-B2 | Triazole PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507832-B2 | Triazole PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-03-24 | — | — | US | disclosed |
| US-20070112045-A1 | Triazole ppar modulators | ELI LILLY AND COMPANY | 2007-05-17 | — | — | US | disclosed |
| US-20070112045-A1 | Triazole ppar modulators | ELI LILLY AND COMPANY | 2007-05-17 | — | — | US | disclosed |
| US-20070112045-A1 | Triazole ppar modulators | ELI LILLY AND COMPANY | 2007-05-17 | — | — | US | disclosed |
| EP-1725231-A1 | TRIAZOLE, OXADIAZOLE AND THIADIAZOLE DERIVATIVES AS PPAR MODULATORS FOR THE TREATMENT OF DIABETES | ELI LILLY AND COMPANY (US) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005065683-A1 | TRIAZOLE, OXADIAZOLE AND THIADIAZOLE DERIVATIVE AS PPAR MODULATORS FOR THE TREATMENT OF DIABETES | ELI LILLY AND COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112045-A1 | Triazole ppar modulators | PPARD, PPARA, PPARG | PPARA 2/4885PPARD 1/4885PPARG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.